Mack Justin K, Bivi Nicoletta
Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285, USA.
Bioanalysis. 2023 Oct;15(19):1179-1191. doi: 10.4155/bio-2023-0095. Epub 2023 Aug 28.
The drug tolerance of an antidrug antibody (ADA) assay for a therapeutic monoclonal antibody was insufficient to meet the level of biotherapeutic expected in sera, and a typical acid dissociation method was inadequate. Other strategies were investigated to dissociate ADA-drug complexes and thereby improve drug tolerance. Having a lower final pH of samples after acid dissociation was shown to greatly improve drug tolerance. This method was shown to improve drug tolerance in the ADA assays for four additional monoclonal antibodies and to better detect ADAs in clinical samples. These findings provide a novel alternative method for improving drug tolerance when other methods are not sufficient.
抗药物抗体(ADA)检测针对治疗性单克隆抗体的药物耐受性不足以满足血清中预期的生物治疗水平,且典型的酸解离方法并不充分。研究了其他策略来解离ADA-药物复合物,从而提高药物耐受性。酸解离后样品的最终pH值较低被证明可大大提高药物耐受性。该方法在另外四种单克隆抗体的ADA检测中显示出可提高药物耐受性,并能更好地检测临床样品中的ADA。当其他方法不足时,这些发现提供了一种提高药物耐受性的新替代方法。